PAQ Therapeutics Secures $77 Million to Advance Cancer Treatment and Doses First Patient in Innovative Trial PAQ Therapeutics has announced a Series B extension funding totaling $77 million and has initiated patient dosing for its Phase 1 trial of PT0511, aimed at treating KRAS-driven cancers.

PAQ Therapeutics Secures $77 Million to Advance Cancer Treatment and Doses First Patient in Innovative Trial #USA #Burlington #PAQ_Therapeutics #KRAS #PT0511